JP2023520516A - 抗trem2抗体の使用方法 - Google Patents

抗trem2抗体の使用方法 Download PDF

Info

Publication number
JP2023520516A
JP2023520516A JP2022560204A JP2022560204A JP2023520516A JP 2023520516 A JP2023520516 A JP 2023520516A JP 2022560204 A JP2022560204 A JP 2022560204A JP 2022560204 A JP2022560204 A JP 2022560204A JP 2023520516 A JP2023520516 A JP 2023520516A
Authority
JP
Japan
Prior art keywords
individual
trem2
antibody
trem2 antibody
cerebrospinal fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520516A5 (cg-RX-API-DMAC7.html
Inventor
ロバート ポール,
マイケル エフ. ウォード,
ホア ロン,
オメル リズワン シッディーキー,
アーノン ローゼンタール,
フェリックス リージャ イェー,
サム ジャクソン,
Original Assignee
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2023520516A publication Critical patent/JP2023520516A/ja
Publication of JP2023520516A5 publication Critical patent/JP2023520516A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022560204A 2020-04-03 2021-04-02 抗trem2抗体の使用方法 Pending JP2023520516A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005130P 2020-04-03 2020-04-03
US63/005,130 2020-04-03
US202063079810P 2020-09-17 2020-09-17
US63/079,810 2020-09-17
PCT/US2021/025626 WO2021203030A2 (en) 2020-04-03 2021-04-02 Methods of use of anti-trem2 antibodies

Publications (2)

Publication Number Publication Date
JP2023520516A true JP2023520516A (ja) 2023-05-17
JP2023520516A5 JP2023520516A5 (cg-RX-API-DMAC7.html) 2024-04-10

Family

ID=75674977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560204A Pending JP2023520516A (ja) 2020-04-03 2021-04-02 抗trem2抗体の使用方法

Country Status (11)

Country Link
US (1) US20230183341A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126953A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023520516A (cg-RX-API-DMAC7.html)
KR (1) KR20230005848A (cg-RX-API-DMAC7.html)
CN (1) CN115667308A (cg-RX-API-DMAC7.html)
AU (1) AU2021247286A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172451A1 (cg-RX-API-DMAC7.html)
IL (1) IL296992A (cg-RX-API-DMAC7.html)
MX (1) MX2022012182A (cg-RX-API-DMAC7.html)
WO (1) WO2021203030A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062436T2 (hu) * 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
CN115003699A (zh) * 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
IL308804A (en) * 2021-05-28 2024-01-01 Vigil Neuroscience Inc TREM2 agonistic biomarkers and methods of using them
JP2024525559A (ja) * 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
MX2024010324A (es) * 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499695A1 (en) * 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CN117624360A (zh) 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524827A (ja) * 2003-06-20 2007-08-30 ジャック イー ジュニ 単一フォトン放出コンピュータ断層撮影システム
WO2018195506A1 (en) * 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE
JP2019519515A (ja) * 2016-05-20 2019-07-11 シーダーズ—シナイ メディカル センター アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法
JP2023505279A (ja) * 2019-12-05 2023-02-08 アレクトル エルエルシー 抗trem2抗体の使用方法
JP2023515478A (ja) * 2020-02-24 2023-04-13 アレクトル エルエルシー 抗trem2抗体の使用方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
CN106465199B (zh) * 2014-09-26 2019-12-13 太阳专利信托公司 设备到设备无线通信方法和用户设备
JP2019531332A (ja) 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) Trem2切断モジュレーター及びその使用
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
MX2024010324A (es) * 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524827A (ja) * 2003-06-20 2007-08-30 ジャック イー ジュニ 単一フォトン放出コンピュータ断層撮影システム
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗trem2抗体及びその使用方法
JP2019519515A (ja) * 2016-05-20 2019-07-11 シーダーズ—シナイ メディカル センター アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法
WO2018195506A1 (en) * 2017-04-21 2018-10-25 Amgen Inc. Trem2 antigen binding proteins and uses thereof
WO2019028292A1 (en) * 2017-08-03 2019-02-07 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USE
JP2023505279A (ja) * 2019-12-05 2023-02-08 アレクトル エルエルシー 抗trem2抗体の使用方法
JP2023515478A (ja) * 2020-02-24 2023-04-13 アレクトル エルエルシー 抗trem2抗体の使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAGYINSZKY E. ET AL., BIOCHIP J, vol. 8(3), JPN6025012498, 2014, pages 155 - 162, ISSN: 0005692691 *
KESTER M. I. ET AL., ALZHEIMER'S REASEARCH & THERAPY, vol. 7:59, JPN6025012502, 2015, ISSN: 0005692690 *
WANG S. ET AL., J. EXP. MED., vol. 217, no. 9, JPN6025012500, 24 June 2020 (2020-06-24), pages 20200785, ISSN: 0005563305 *
WANG Y. ET AL., CELL, vol. Vol.160 Issue 6, JPN6025012501, 2015, pages 1061 - 1071, ISSN: 0005692689 *

Also Published As

Publication number Publication date
IL296992A (en) 2022-12-01
WO2021203030A3 (en) 2021-11-18
AU2021247286A1 (en) 2022-10-20
KR20230005848A (ko) 2023-01-10
CN115667308A (zh) 2023-01-31
BR112022019892A2 (pt) 2022-12-13
CA3172451A1 (en) 2021-10-07
WO2021203030A2 (en) 2021-10-07
EP4126953A2 (en) 2023-02-08
US20230183341A1 (en) 2023-06-15
MX2022012182A (es) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7554247B2 (ja) 抗trem2抗体及びその使用方法
US20230183341A1 (en) Methods of use of anti-trem2 antibodies
US20250084165A1 (en) Methods of use of anti-trem2 antibodies
JP2023090751A (ja) 神経変性疾患を治療するためのcd14アンタゴニスト抗体
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
US20230024528A1 (en) Methods of use of anti-trem2 antibodies
JP7745557B2 (ja) 抗trem2抗体の使用方法
CN114019170A (zh) 用于阿尔茨海默氏病的高剂量治疗
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
HK40087465A (en) Methods of use of anti-trem2 antibodies
EA050276B1 (ru) Способы применения антител к trem2
HK40067504A (en) High dose treatments for alzheimer's disease
HK40079646A (en) Methods of use of anti-trem2 antibodies
EA051513B1 (ru) Способы применения антител к сортилину

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250924